Fluorescentia develops a pharmacogenetics platform that utilizes fluorescence spectroscopy to measure and differentiate active and inactive platinum drug complexes in blood samples. This technology addresses the limitations of current dosing methods by providing precise pharmacokinetic data, enabling tailored chemotherapy dosing for improved patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods for dosing platinum-based chemotherapy drugs rely on body-surface area formulas, which do not account for individual patient variations in drug pharmacokinetics. This can lead to suboptimal dosing, increasing the risk of side effects or reducing treatment effectiveness, particularly in specific patient groups like pediatric, obese, and tall individuals. Existing technologies also have limitations in accurately monitoring platinum concentrations in the blood.
Solution
Fluorescentia has developed a pharmacogenetic platform that uses fluorescence spectroscopy to measure and differentiate active and inactive platinum drug complexes in blood samples. This technology provides insights into platinum drug pharmacokinetics, enabling individualized dosing adjustments for safer and more effective chemotherapy. The platform utilizes readily available spectrofluorometer equipment and offers a cost-effective alternative to ICP-MS. The technology generates data that can be used to develop precision dosing models and provides valuable endpoint datasets for clinical trials involving platinum-based drugs.
Target Audience
The primary target audience includes oncologists, hospitals, and clinical researchers involved in platinum-based chemotherapy treatments and clinical trials.
Features
- Measures and distinguishes multiple platinum drug complexes in blood samples using fluorescence spectroscopy.
- Differentiates between active and inactivated forms of platinum drugs.
- Provides data on blood concentrations of platin drugs to improve treatment decision-making.
- Offers a cost-effective alternative to ICP-MS by utilizing readily available spectrofluorometry equipment.
- Generates datasets for clinical trials with arms that include the use of platins.
- Can be used to develop precision dosing models for individualized treatment.